HIGHLIGHTS
- who: Leila Takahashi-Ruiz and colleagues from the Department of Pharmacology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA have published the research: The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models, in the Journal: (JOURNAL)
- what: The authors demonstrate that eribulin is unique from paclitaxel in its ability to enhance expression of the immunogenic cytokine interferon beta (IFNu03b2) in combination with STING agonists in both immune cells and TNBC models including profound synergism with ADU-S100 and E7766 which are currently . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.